Montserrat Baldan-Martin1, Fernando de la Cuesta1, Gloria Alvarez-Llamas2, Laura Gonzalez-Calero2, Gema Ruiz-Hurtado3, Rafael Moreno-Luna1, Laura Mourino-Alvarez1, Tamara Sastre-Oliva1, Julian Segura4, Luis R Padial5, Fernando Vivanco6, Luis M Ruilope7, Maria G Barderas1. 1. Laboratorio de Fisiopatologia Vascular, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain. 2. Departamento de Inmunologia, IIS-Fundacion Jimenez Diaz, Madrid, Spain. 3. Unidad de Hipertension, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Pluridisciplinar, Universidad Complutense de Madrid, Spain. 4. Unidad de Hipertension, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain. 5. Departamento de Cardiologia, Complejo Hospitalario de Toledo, SESCAM, Toledo, Spain. 6. Departamento de Inmunologia, IIS-Fundacion Jimenez Diaz, Madrid, Spain; Departamento de Bioquimica y Biologia Molecular I, Universidad Complutense, Madrid, Spain. 7. Unidad de Hipertension, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: ruilope@ad-hocbox.com.
Abstract
BACKGROUND: High albuminuria is a strong predictor of development of cardiovascular events in hypertensive patients. The search for predictors identifying patients at risk of developing high albuminuria or presenting a more rapid progression in this parameter may represent an effective strategy for adequate intervention and better outcome. METHODS AND RESULTS: Initially we investigated 24 patients presenting with normoalbuminuria, de novo albuminuria and sustained albuminuria. Plasma proteomics disclosed an upregulation of ceruloplasmin (CP), haptoglobin (HP) and alpha 1-acid glycoprotein (ORM1) that in a second step were selected for validation using turbidimetry assay in a cohort of 105 subjects. The validation showed that HP and ORM1 proteins were increased in patients presenting with very high albuminuria and potential irreversible kidney damage. CP and HP correlated positively with albuminuria values in normoalbuminuric patients. Finally, the levels of ORM1 and CP were increased in patients who progressed in their levels of albuminuria. CONCLUSIONS: Our findings show that these proteins may potentially be useful for predicting the development of high albuminuria and to monitor renal damage.
BACKGROUND:High albuminuria is a strong predictor of development of cardiovascular events in hypertensivepatients. The search for predictors identifying patients at risk of developing high albuminuria or presenting a more rapid progression in this parameter may represent an effective strategy for adequate intervention and better outcome. METHODS AND RESULTS: Initially we investigated 24 patients presenting with normoalbuminuria, de novo albuminuria and sustained albuminuria. Plasma proteomics disclosed an upregulation of ceruloplasmin (CP), haptoglobin (HP) and alpha 1-acid glycoprotein (ORM1) that in a second step were selected for validation using turbidimetry assay in a cohort of 105 subjects. The validation showed that HP and ORM1 proteins were increased in patients presenting with very high albuminuria and potential irreversible kidney damage. CP and HP correlated positively with albuminuria values in normoalbuminuric patients. Finally, the levels of ORM1 and CP were increased in patients who progressed in their levels of albuminuria. CONCLUSIONS: Our findings show that these proteins may potentially be useful for predicting the development of high albuminuria and to monitor renal damage.
Authors: Luis Rodriguez-Padial; Finn Akerström; María G Barderas; Fernando Vivanco; Miguel A Arias; Julian Segura; Luis M Ruilope Journal: Diseases Date: 2017-12-08
Authors: Fernando de la Cuesta; Montserrat Baldan-Martin; Rafael Moreno-Luna; Gloria Alvarez-Llamas; Laura Gonzalez-Calero; Laura Mourino-Alvarez; Tamara Sastre-Oliva; Juan A López; Jesús Vázquez; Gema Ruiz-Hurtado; Julian Segura; Fernando Vivanco; Luis M Ruilope; Maria G Barderas Journal: Oncotarget Date: 2017-02-28
Authors: Laura Gonzalez-Calero; Paula J Martínez; Marta Martin-Lorenzo; Montserrat Baldan-Martin; Gema Ruiz-Hurtado; Fernando de la Cuesta; Eva Calvo; Julian Segura; Juan Antonio Lopez; Jesús Vázquez; Maria G Barderas; Luis M Ruilope; Fernando Vivanco; Gloria Alvarez-Llamas Journal: Oncotarget Date: 2017-07-04
Authors: Montserrat Baldan-Martin; Juan A Lopez; Nerea Corbacho-Alonso; Paula J Martinez; Elena Rodriguez-Sanchez; Laura Mourino-Alvarez; Tamara Sastre-Oliva; Tatiana Martin-Rojas; Raul Rincón; Eva Calvo; Jesus Vazquez; Fernando Vivanco; Luis R Padial; Gloria Alvarez-Llamas; Gema Ruiz-Hurtado; Luis M Ruilope; Maria G Barderas Journal: Sci Rep Date: 2018-03-19 Impact factor: 4.379